poisar

Stocks · News reference

Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $25

Benzinga Newsdesk

Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target from $24 to $25.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ATOS
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGAR

    8-K filing — ATOSSA THERAPEUTICS, INC. (ATOS)

    Filed: 2026-10-09 AccNo: 0001193125-26-418560 Size: 566 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.03: Material Modifications to Rights of Security Holders Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

    ATOS
  3. Benzinga Newsdesk

    Atossa Therapeutics Q2 EPS $(0.95) Beats $(1.02) Estimate

    Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.95) per share which beat the analyst consensus estimate of $(1.02) by 6.86 percent. This is a 171.43 percent decrease over losses of $(0.35) per share

    ATOS